Gastric Cancer Market Report 2026

The gastric cancer market size has grown rapidly in recent years. It will grow from $3.64 billion in 2025 to $4.19 billion in 2026 at a compound annual growth rate (CAGR) of 15.2%. The growth in the historic period can be attributed to high prevalence of helicobacter pylori infection, smoking and dietary risk factors, expansion of chemotherapy usage, hospital-based oncology care growth, development of surgical oncology.

The gastric cancer market size is expected to see rapid growth in the next few years. It will grow to $7.29 billion in 2030 at a compound annual growth rate (CAGR) of 14.8%. The growth in the forecast period can be attributed to advancements in immuno-oncology, growth in precision diagnostics, rising cancer screening programs, increasing aging population, development of novel targeted drugs. Major trends in the forecast period include rising adoption of targeted and immunotherapies, increased focus on early diagnosis and screening, expansion of personalized cancer treatment approaches, growing use of combination therapy regimens, improved multidisciplinary cancer care models.

The increasing prevalence of obesity is expected to support the growth of the gastric cancer market in the coming years. Obesity is a medical condition marked by excessive accumulation of body fat, commonly defined by a body mass index (BMI) of 30 or above, and is associated with multiple health complications. Obesity rates are rising due to factors such as unhealthy dietary habits, insufficient physical activity, sedentary lifestyles, environmental influences, and genetic susceptibility. Excess adipose tissue, particularly visceral fat in the abdominal region, is linked to a higher risk of gastric cancer, as obesity promotes chronic inflammation and metabolic abnormalities that are associated with cancer development, thereby increasing demand for gastric cancer treatments. For example, in March 2024, the World Health Organization (WHO), a Switzerland-based intergovernmental body, reported that one in eight people globally - more than 1 billion individuals - are living with obesity. Consequently, the rising obesity burden is driving growth in the gastric cancer market.

Key players in the gastric cancer market are concentrating on the development of advanced technologies, including companion diagnostic assays, to enable more personalized treatment approaches. A companion diagnostic assay is a test designed to identify patients who are most likely to benefit from a particular therapy based on the presence of specific biomarkers. For instance, in October 2024, F. Hoffmann-La Roche Ltd., a Switzerland-based pharmaceutical company, announced U.S. Food and Drug Administration (FDA) approval of the VENTANA CLDN18 (43-14A) RxDx Assay, the first immunohistochemistry (IHC) companion diagnostic for evaluating CLDN18 protein expression in gastric and gastroesophageal junction (GEJ) adenocarcinoma. The assay determines patient eligibility for targeted therapy with VYLOY (zolbetuximab) by measuring CLDN18 protein variants, primarily CLDN18.2. When used with the OptiView DAB IHC Detection Kit on the BenchMark ULTRA platform, the test supports personalized care and broadens treatment options for patients with gastric and GEJ adenocarcinoma.

In January 2023, Leap Therapeutics, Inc., a U.S.-based biotechnology company specializing in targeted oncology treatments, acquired Flame Biosciences, Inc. for an undisclosed amount. Through this acquisition, Leap aimed to strengthen its oncology pipeline by incorporating Flame’s clinical-stage anti-Claudin 18.2 antibody program, FL-301, thereby gaining exposure to a well-validated gastric and pancreatic cancer target. Flame Biosciences, a US-based company, focuses on the development of precision oncology therapeutics, including its Claudin 18.2-targeted antibody, which is particularly relevant for gastric and gastroesophageal cancer indications.

Major companies operating in the gastric cancer market are F. Hoffmann La Roche Ltd., Merck And Co. Inc., AbbVie Inc., Sanofi S.A., Bristol Myers Squibb Company, Novartis AG, GlaxoSmithKline Plc, Eli Lilly and Company, Amgen Inc., Gilead Sciences Inc., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Ipsen Biopharmaceuticals Inc., Ono Pharmaceutical Co. Ltd., Taiho Oncology Inc., Taiho Pharmaceuticals Co. Ltd., Boehringer Ingelheim, Biocon Limited, Jiangsu Hengrui Medicine Co Ltd, BeiGene Ltd.

North America was the largest region in the gastric cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastric cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the gastric cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the gastric cancer market by increasing costs of imported oncology drugs, diagnostic imaging equipment, and laboratory reagents. Hospitals and cancer treatment centers in developed regions are most affected due to reliance on imported therapeutics. These tariffs raise treatment costs by increasing expenses for chemotherapy, targeted therapies, and imaging-based disease monitoring, placing pressure on oncology care budgets and patient affordability. However, they encourage domestic oncology drug manufacturing, supporting local production of cancer therapeutics and reducing long-term dependence on imported treatments.

The gastric cancer market research report is one of a series of new reports that provides gastric cancer market statistics, including gastric cancer industry global market size, regional shares, competitors with a gastric cancer market share, detailed gastric cancer market segments, market trends and opportunities, and any further data you may need to thrive in the gastric cancer industry. This gastric cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Gastric cancer is a malignant tumor that develops in the lining of the stomach. It typically starts in the mucosa, the stomach’s innermost layer, and may spread to deeper layers, surrounding tissues, or distant organs if not detected and treated early. The disease is commonly linked to risk factors such as chronic infection with Helicobacter pylori, smoking, excessive alcohol intake, poor dietary habits, and genetic susceptibility.

The main types of gastric cancer include adenocarcinoma, lymphoma, gastrointestinal stromal tumors, carcinoid tumors, and others. Adenocarcinoma is the most prevalent form, arising from the glandular cells of the stomach lining. Diagnosis involves methods such as endoscopy, biopsy, imaging tests, exploratory surgery, and others, while treatment options include surgery, radiation therapy, chemotherapy, targeted therapy, palliative care, and others. These treatments are distributed through various channels, including hospital pharmacies, specialty pharmacies, retail pharmacies, and others.

The gastric cancer market consists of revenues earned by entities by providing services such as cancer screening and early detection, genetic testing, personalized treatment planning, and research and development services. The market value includes the value of related goods sold by the service provider or included within the service offering. The gastric cancer market also includes sales of chemotherapeutic drugs, radiation therapy equipment, nutritional support products, surgical tools, and instruments. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.